Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Oct 19, 2021 10:00 AM - Oct 20, 2021 5:00 PM

(US Eastern Standard Time)

DIA Canadian Annual Meeting

The Canadian Annual Meeting now includes a track for Pharmacovigilence and Risk Management Strategies!

Session 2 Track B: Clinical Trials Innovation in Canada

Session Chair(s)

Fiona M Frappier, PhD

Fiona M Frappier, PhD

Senior Policy Analyst

Health Canada, Canada

Mandy  Collier

Mandy Collier

Director, Health Products and Food Branch

Health Canada, Canada

Clinical trials continue to try new and innovative approaches to improve trial outcomes and patient health, and the need to modernize the way we regulate these trials in Canada has become clear. This session will provide an overview of Health Canada’s approach to modernization of clinical trial regulations, include case studies of how patients have contributed to resource development and describe how decentralized trials have the potential to transform the way we conduct clinical research. The objective of this session is to provide an overview of how industry, government and research organizations are aiming to modernize clinical development.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Outline Health Canada’s Clinical Trial Modernization Initiative
  • Describe new approaches to decentralized trials
  • Address patient considerations in improving clinical trials

Speaker(s)

Carole  Legare, MD

Health Canada’s Approach to Clinical Trial Modernization

Carole Legare, MD

Health Canada, Canada

Director, Office of Clinical Trials, TPD

Dawn P. Richards, PhD

Engaging Patients and the Public with Clinical Trials: Two Case Studies to Demonstrate Resources and Tools to Help Your Work

Dawn P. Richards, PhD

Clinical Trials Ontario, Canada

Director, Patient and Public Engagement

Scott  Askin, MSc

Modernizing Clinical Trials through the Global Adoption of Decentralized Clinical Trials

Scott Askin, MSc

Novartis Pharma AG, Switzerland

Global Program Regulatory Director

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.